Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer

Non-small cell lung cancer (NSCLC) harboring activating EGFR mutations were initially treated by first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), unfortunately, the efficacy of these drugs is limited, mostly frequent due to T790M mutation. Although osimertinib has been approved to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Peiyuan, Qu, Yana, Wang, Yuna, Wang, Jing, Wang, Xuanjun, Sheng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176237/
https://www.ncbi.nlm.nih.gov/pubmed/34093797
http://dx.doi.org/10.7150/jca.54574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176237/
https://www.ncbi.nlm.nih.gov/pubmed/34093797
http://dx.doi.org/10.7150/jca.54574

Ejemplares similares